Rebecca M Lynch

List of Publications by Year
in descending order

45	4,364	279798 23	254184 43
papers	citations	h-index	g-index

50	50	50	4796
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques. Npj Vaccines, 2021, 6, 34.	6.0	7
2	HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nature Communications, 2021, 12, 165.	12.8	60
3	Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV. Molecular Therapy - Methods and Clinical Development, 2020, 19, 78-88.	4.1	10
4	Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV. Journal of Virology, 2020, 95, .	3.4	5
5	Embracing diversity: how can broadly neutralizing antibodies effectively target a diverse HIV-1 reservoir?. Current Opinion in Pharmacology, 2020, 54, 173-178.	3.5	4
6	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. Journal of Clinical Investigation, 2020, 130, 3299-3304.	8.2	24
7	Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-BarrÃ© Syndrome. Journal of Infectious Diseases, 2019, 219, 26-30.	4.0	21
8	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. Scientific Reports, 2019, 9, 14696.	3.3	30
9	Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. Journal of Virology, 2019, 93, .	3.4	27
10	Co-circulation of dengue, chikungunya, and Zika viruses in Colombia from 2008 to 2018. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2019, 43, 1.	1.1	27
11	Intra- and inter-individual HIV diversity limits the application of the intact proviral detection assay (IPDA). Journal of Virus Eradication, 2019, 5, 9.	0.5	0
12	Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs. Journal of Virology, 2019, 93, .	3.4	24
13	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight, 2019, 4, .	5.0	25
14	Authorsâ€™ response to the letter to the editor entitled: Co-circulation of dengue, chikungunya, and Zika viruses and cross-protection. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2019, 43, 1.	1.1	4
15	Second-trimester Ultrasound and Neuropathologic Findings in Congenital Zika Virus Infection. Pediatric Infectious Disease Journal, 2018, 37, 1290-1293.	2.0	6
16	Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. Journal of Virology, 2018, 92, .	3.4	20
17	Long-term clinical outcomes of Zika-associated Guillain-BarrÃ© syndrome. Emerging Microbes and Infections, 2018, 7, 1-4.	6.5	11
18	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	2.5	24

#	Article	IF	Citations
19	Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Current HIV/AIDS Reports, 2017, 14, 54-62.	3.1	18
20	Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection. PLoS ONE, 2017, 12, e0173577.	2.5	5
21	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal of Medicine, 2016, 375, 2037-2050.	27.0	391
22	B cells in HIV pathogenesis. Current Opinion in Infectious Diseases, 2016, 29, 23-30.	3.1	10
23	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology, 2016, 90, 76-91.	3.4	205
24	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
25	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
26	HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies. Journal of Virology, 2015, 89, 4201-4213.	3.4	121
27	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. Science Translational Medicine, 2015, 7, 298ra120.	12.4	119
28	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature Communications, 2015, 6, 6565.	12.8	77
29	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell, 2015, 161, 470-485.	28.9	226
30	Isolation of Monoclonal Antibodies from a SHIV-AD8 Infected Rhesus Macaque with Broad Neutralizing Activity. AIDS Research and Human Retroviruses, 2014, 30, A78-A78.	1.1	0
31	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266
32	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. Journal of Clinical Investigation, 2014, 124, 1835-1843.	8.2	93
33	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
34	HIV vaccine research and discovery in the nonhuman primates model. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	13
35	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. Journal of Virology, 2012, 86, 7588-7595.	3.4	123
36	SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination. Blood, 2011, 118, 5803-5812.	1.4	45

#	Article	IF	Citations
37	The B Cell Response Is Redundant and Highly Focused on V1V2 during Early Subtype C Infection in a Zambian Seroconverter. Journal of Virology, 2011, 85, 905-915.	3.4	66
38	Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology, 2010, 404, 59-70.	2.4	30
39	Donor and Recipient Envs from Heterosexual Human Immunodeficiency Virus Subtype C Transmission Pairs Require High Receptor Levels for Entry. Journal of Virology, 2010, 84, 4100-4104.	3.4	53
40	Appreciating HIV Type 1 Diversity: Subtype Differences in Env. AIDS Research and Human Retroviruses, 2009, 25, 237-248.	1.1	69
41	Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways. PLoS Pathogens, 2009, 5, e1000594.	4.7	172
42	107 Escape from Neutralizing Antibody in Early Subtype C HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, .	2.1	0
43	Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DECâ€205/CD205â€positive mouse dendritic cells. European Journal of Immunology, 2008, 38, 20-29.	2.9	59
44	Maintenance of CD4+ T cell TCR VÎ² repertoire heterogeneity is characteristic of apathogenic SIV infection in non-human primate model of AIDS. Virology, 2007, 369, 324-328.	2.4	3
45	A Dominant Complement Fixation Pathway for Pneumococcal Polysaccharides Initiated by SIGN-R1 Interacting with C1q. Cell, 2006, 125, 47-58.	28.9	204